The lactacin F complex, composed of LafA and LafX peptides, is produced by Lactobacillus johnsonii VPI 11088 and is active against five other Lactobacillus species and Enterococcus faecalis. The genetic determinants encoding the lactacin F complex are organized in a 1-kb polycistronic operon which comprises three genes, lafA, lafX, and ORFZ (encoding the putative immunity protein). The lafA and lafX genes encode the bacteriocin precursors with N-terminal extensions characterized by a Gly-Gly ؊1
Growing interest in new and improved preservatives for food and dairy products has fueled investigation of bacteriocins produced by lactic acid bacteria. An explosion of research in this area has provided a wealth of new information focusing on three major areas: identification of new bacteriocins with broad inhibitory spectra; characterization of the processing, excretion, and regulatory mechanisms; and discovery of the mode of action. Bacteriocins are proteinaceous antimicrobial compounds (36) . On the basis of their biochemical characteristics, bacteriocins have been categorized into four different classes (16) . The class II bacteriocins are produced by a wide variety of genera, yet they share the following biochemical characteristics: heat stability, the presence of small membraneactive peptides predicted to form amphiphilic helices or beta sheets, the absence of dehydro amino acid residues and lanthionine bridges, and a bacteriocin precursor characterized by a Gly-Gly Ϫ1 proteolytic processing site at the C terminus of the N-terminal extension. Examples of class II bacteriocins include pediocin PA-1; lactococcins A, B, G, and M; sakacins A and P; curvacin A; leucocin A; lactacin F; carnobacteriocins A, BM1, and B2, and others (reviewed in reference 16).
The leader peptides of class II bacteriocins share many features. These N-terminal sequences are usually 18 to 24 amino acids long (reviewed in reference 16) but are not typical of those cleaved by classic signal peptidases (14, 38, 39) . The sequence similarity among many of the class II bacteriocin N-terminal extensions is striking and includes the following: hydrophobic residues in positions Ϫ4, Ϫ7, Ϫ12, and Ϫ15; a core of charged amino acids in positions Ϫ8 to Ϫ10; and polar or charged residues at the N terminus (10, 28) . Furthermore, the N-terminal extensions of many bacteriocin precursors have specific amino acid residues conserved in certain positions: Gly , and Leu Ϫ12 (13, 28) . Of all of the class II bacteriocins, the N-terminal leader sequences of the lactacin F peptides and the carnobacteriocins (A, BM1, and B2) have the greatest similarity, suggesting that systems for proteolytic processing and export may be interchangeable.
Lactacin F, produced by Lactobacillus johnsonii VPI 11088 (ATCC 11506), is a membrane-active bacteriocin consisting of two peptides, LafA and LafX (1, 4, 10) . The lactacin F operon is composed of three genes. The bacteriocin structural genes, lafA and lafX, are adjacent to one another and followed by ORFZ, which encodes the putative immunity protein (10, 23) . Carnobacterium piscicola LV17 (NCFB 2855) was originally isolated as an atypical Lactobacillus strain in a study of the bacterial composition of vacuum-packaged meat by Shaw and Harding (34) and later identified as C. piscicola by Ahn and Stiles (2) . C. piscicola LV17 produces three bacteriocins, carnobacteriocins A, BM1, and B2. Carnobacteriocins A and B2 are encoded by plasmids pCP49 and pCP40, respectively, whereas BM1 is encoded from a genomic fragment (2, 28, 41) . While different in ecological origins and fermentation characteristics, these two species produce bacteriocins with very similar N-terminal extensions.
The objective of this study was to determine if lactacin F could be expressed in the bacteriocin-producing strain of C. piscicola.
MATERIALS AND METHODS
Bacteriology. The bacterial strains and plasmids used in this study are described in Table 1 . Cultures were maintained and stored at Ϫ20ЊC in 20% glycerol. The organisms used in this study were propagated as follows: Lactobacillus strains, at 37ЊC in Lactobacilli MRS or APT medium (Difco Laboratories, Detroit, Mich.); Carnobacterium strains, at 25ЊC in APT medium; Enterococcus faecalis and Listeria monocytogenes, at 37ЊC in brain heart infusion medium (Difco); and Lactococcus and Pediococcus strains, at 30ЊC in M17 (Difco) containing 5 g of glucose per liter (M17G). Agar growth medium was prepared by adding either 0.75 or 1.5% granular agar (BBL Microbiology Systems, Cockeysville, Md.) to broth medium. When grown on agar medium, Lactobacillus and Carnobacterium strains were propagated under anaerobic gas (85% N 2 , 10% CO 2 , 5% H 2 ). Lactobacillus strains harboring recombinant plasmids were grown in MRS broth with 3 g of erythromycin per ml. Carnobacterium transformants were selected on APT agar and cultured in broth supplemented with 5 g of erythromycin per ml. Escherichia coli SURE (Stratagene, La Jolla, Calif.) was propagated at 37ЊC in Luria-Bertani medium (31) with 10 g of tetracycline per ml. When appropriate for selection of clones, X-Gal (5-bromo-4-chloro-3-indolyl-␤-D-galactopyranoside) and IPTG (isopropyl-␤-D-thiogalactopyranoside) were used at a concentration of 50 g/ml (31). Erythromycin-resistant (Em   r   ) transformants of E. coli were selected on brain heart infusion agar with 200 g of erythromycin per ml (26) .
Bacteriocin assay. Prior to bacteriocin assays, frozen stocks of recombinant strains of Carnobacterium spp. were streaked onto selective APT agar, incubated for 24 to 36 h, transferred into selective APT broth, and incubated for 18 to 24 h. C. piscicola LV17 and LV17C and Lactobacillus recombinant strains were inoculated (1% from frozen stocks) into broth, incubated for 18 to 24 h, subcultured, and incubated for 18 to 24 h. Bacteriocin production by Carnobacterium strains was assayed by spotting 5 l from a broth culture onto APT agar (1.5%) and incubating at 25ЊC for 24 h under anaerobic gas. The plate was then overlaid with 5.5 ml of the appropriate type of agar (0.75%) containing a 1% inoculum of indicator cells prepared under the general conditions described for Carnobacterium and Lactobacillus strains. Overlaid plates were incubated at optimal temperatures for 12 to 18 h before reading of the results. For assays of bacteriocin complementation between Lactobacillus and Carnobacterium clones, 5 l of Carnobacterium cultures was spotted onto APT agar and grown under anaerobic conditions for 24 h at 25ЊC. Lactobacillus cultures (5 l) were then spotted close to the existing Carnobacterium colony, and the agar plates were incubated anaerobically at 37ЊC for an additional 6 to 8 h. Indicators were then overlaid as described above. Molecular transformation and cloning. E. coli and Lactobacillus cells were prepared for electrotransformation by following the protocols outlined by Dower et al. (7) and Raya et al. (30), respectively. Carnobacterium cells were prepared for electrotransformation by using the latter protocol with the following modifications: electroporation buffer was composed of 0.5 M sucrose and 2.5 mM CaCl 2 ; freshly inoculated medium was incubated at 25ЊC for 4 to 5 h prior to preparation of electrocompetent cells; after washing once with sterile picopure water (50 ml) and twice with electroporation buffer (25 ml and then 10 ml), the original 100-ml culture was resuspended in 250 l of electroporation buffer and 50 l of this cell suspension was used for electroporation. The cells were electroporated in 0.2-cm cuvettes with a Gene Pulser apparatus (Bio-Rad, Richmond, Calif.) set at 25 F, 200 ⍀ and 2.45 kV for E. coli or 2.1 kV for Lactobacillus and Carnobacterium strains. After electroporation, the cells were incubated in the appropriate nonselective medium for 1 h (E. coli) or for 2 to 4 h (Lactobacillus and Carnobacterium strains), prior to plating on selective agar media.
Plasmid DNA was isolated from E. coli as described by Sambrook et al. (31) and from Lactobacillus spp. as described by Walker and Klaenhammer (40) . The Lactobacillus protocol was modified for Carnobacterium strains as follows: lysozyme concentration was increased to 20 mg/ml, the high salt solution was replaced by a mixture of 50 l of 2 M Tris-HCl (pH 7.0) and 70 l of 5 M NaCl, phenol extractions were shaken at room temperature for 1 h, and DNA was precipitated with 95% ethanol at Ϫ20ЊC.
The lactacin F operon was cloned into pTRKH2 for the heterologous expression experiments. Restriction endonucleases and T4 ligase were used as recommended by the manufacturer (New England Biolabs, Beverly, Mass.). pTRKH2 and pTRK160 (pBluescript::2.3-kb lafAX operon) were digested with SalI and BglII or BamHI, respectively. Both fragment and vector were purified from 0.8% agarose gels (wt/vol; 1ϫ Tris-acetate-EDTA buffer, pH 8.0), using the GENE CLEAN II Kit (Bio 101, La Jolla, Calif.), and ligated with T4 ligase (New England Biolabs). The ligation mix was used to transform E. coli SURE (Stratagene). Seventeen Em r transformants were analyzed with one, NCK718, containing the recombinant plasmid of expected size (pTRK386, 9.2 kb). Restriction analysis confirmed the presence of the cloned 2.3-kb lafAX operon fragment. The fidelity of pTRK386 was confirmed by electroporation into NCK65, a mutant of VPI 11088 with a chromosomal deletion eliminating the lactacin F operon from the genome (4, 22, 23) , in which pTRK386 directed production of lactacin F.
RESULTS
Cloning the lactacin F operon into C. piscicola. C. piscicola LV17 is the wild-type producer of three carnobacteriocins, A, BM1, and B2 (designated CbnAB ϩ ) (2, 28, 41) . C. piscicola LV17C, a plasmidless derivative of LV17, is phenotypically bacteriocin negative (CbnAB Ϫ ); however, the structural gene for carnobacteriocin BM1 is located on the chromosome (2, 28). pTRK386 was introduced into LV17 and LV17C. As a negative control, pTRK201, containing truncated lafA (lafA886) (Fig. 1) , was also electrotransformed into LV17C. Acquisition of the recombinant plasmids in the Carnobacterium transformants was confirmed by analysis of plasmid profiles (data not shown).
The bacteriocin-producing phenotypes of LV17 (pTRK386 Fig. 2A and B Fig. 2A and B) . LV17(pTRK386) simultaneously produced CbnAB ϩ inhibition of C. divergens LV13 at levels similar to that of the wild-type strain LV17 (Fig. 2C) . LV17C, LV17C(pTRK201) (data not shown), and LV17C(pTRK386) are all CbnAB Ϫ and do not inhibit the Laf s indicators (Fig. 2 ). These data indicated that the processing and export machinery of the carnobacteriocins is required for simultaneous production of active lactacin F peptides.
Cloning of components of the lactacin F operon into C. piscicola. The lactacin F complex is composed of two peptides, LafA and LafX (4, 10). The lafA and lafX genes were separately cloned into C. piscicola to determine if the individual peptides could be produced by the heterologous host. Strain LV17C was included as a negative control because the LV17C(pTRK386) transformant was unable to produce lactacin F.
The lafA gene, cloned into pTRK203 (lafA ϩ ) ( Fig. 1) , was introduced into LV17 and LV17C. When LV17(pTRK203) (cbnAB ϩ lafA ϩ ) and LV17C(pTRK203) (cbnAB lafA ϩ ) were assayed for LafA activity against L. helveticus 87 (LafA s and Laf s ) (4), bacteriocin production was not detected (Fig. 2B) . However, when complemented with the LafX-producing L. johnsonii clone, NCK65(pTRK92), a zone of lactacin F inhibition was observed between the NCK65 and LV17 recombinants (Fig. 3) . When LV17C(pTRK203) was plated next to NCK65(pTRK92), complementation of bacteriocin activity was not observed (Fig. 3) . These data confirmed that the LafA peptide was processed and excreted by the carnobacteriocin's machinery; however, the levels appeared extremely low because LafA activity from LV17(pTRK203) alone could not be detected with L. helveticus 87 as the indicator (Fig. 2B) .
The lafX gene, encoding the second peptide of the lactacin F complex, was cloned into pTRK92 (lafX ϩ ) ( Fig. 1) and transformed into LV17 and LV17C. When complemented with the LafA-producing L. johnsonii clone, NCK65(pTRK203), a large zone of lactacin F activity was observed between the Lactobacillus and Carnobacterium recombinant strains (Fig. 3) , but complementation did not occur between NCK65(pTRK203) and LV17C(pTRK92) (Fig. 3) . These data confirmed that C. piscicola LV17 can produce both LafA and LafX, but in the absence of the secretion machinery in LV17C, these peptides are not produced. Comparing the zones of complementation between recombinants LafX ϩ NCK65(pTRK92) and LafA ϩ FIG. 1. The lactacin F operon and constructions cloned into Carnobacterium strains. DNA fragments subcloned into pTRKH2 (26) to construct pTRK386 and pTRK92 are shown. DNA fragments subcloned into pGKV210 (37) to construct pTRK201 and pTRK203 are also shown. ‫,ء‬ frameshift mutation (4); ã, promoter; s, rho-independent terminator (10).
VOL. 61, 1995 LACTACIN F PRODUCTION BY CARNOBACTERIUM PISCICOLA 1373 LV17(pTRK203) and also between LafA ϩ NCK65(pTRK203) and LafX ϩ LV17(pTRK92), the level of LafX production by C. piscicola LV17 appears to be greater than that of LafA (Fig. 3) . However, in L. johnsonii, the levels of LafA and LafX production appear to be similar (Fig. 3) . Even though LV17(pTRK203) and LV17(pTRK92) produce LafA and LafX, respectively (Fig. 3) , there was no zone of lactacin F activity between these cultures in a homologous complementation assay (Fig. 2) , suggesting that LafA production is low and a limiting factor in this case. The carnobacteriocin phenotypes of LV17(pTRK203) and LV17(pTRK92) were also assayed. In addition to producing LafA and LafX, respectively, the LV17 transformants simultaneously produced carnobacteriocins and inhibited the indicator strain at levels equivalent to those of the parental strain LV17. Therefore, concurrent production of the native carnobacteriocins and LafA, LafX, or both, did not retard maturation or excretion of the carnobacteriocins (Fig. 2C) . LV17C(pTRK203) and LV17C(pTRK92) were CbnAB Ϫ as expected (Fig. 2C) .
FIG. 2. Bacteriocin production by C. piscicola LV17 (CbnAB
Inhibitory spectra of recombinants producing mixed components of two bacteriocin systems. Because LV17 produces LafA, LafX, and the lactacin F complex simultaneously with the native carnobacteriocins, the possibility that combined bacteriocin systems and/or components thereof could interact to form heterologous complexes was evaluated. New complexes might be effective against strains normally insensitive to the native bacteriocins. Therefore, LV17(pTRK386) (CbnAB . These data indicate that the heterologous peptide combinations did not increase or expand the inhibitory spectrum beyond those indicator strains examined in this study.
DISCUSSION
C. piscicola LV17 is capable of simultaneous production of multiple bacteriocins. LV17 naturally produces three different bacteriocins, carnobacteriocins A, BM1, and B2 (28, 41) . When the lactacin F operon or components thereof were cloned into C. piscicola LV17, low levels of production of active LafA and/or LafX were observed. The native carnobacteriocins and the heterologous lactacin F peptides are produced concurrently, and expression of the non-native bacteriocin does not retard the level of carnobacteriocin production (Fig. 2) . Consequently, LV17 is capable of producing five bacteriocins simultaneously. However, it appears that the lactacin F peptides are expressed at a lower level than the carnobacteriocins, suggesting that their bacteriocin precursors do not compete efficiently for the native processing and excretion recognition signals or that the transcription and translation signals are not proficiently read in this background. Expression of both the native and non-native bacteriocins appears to be dependent on the presence of the carnobacteriocin processing and export mechanisms, which are encoded on pCP40 and pCP49 (3, 28) . LV17C, a plasmidless mutant of LV17 that does not produce carnobacteriocin, failed to produce active lactacin F after introduction of the laf operon.
The processing and secretion systems of pediocin PA-1 and lactococcin A, both class II bacteriocins, have been studied in detail. In both cases, the two gene products required to effect bacteriocin production show homology to the hemolysin export system of E. coli (18, 21, 35) . The export of hemolysin is accomplished through an ABC transporter system, so named from the characteristic ATP-binding cassette common to one of the proteins involved (reviewed in reference 9). ABC transporters export numerous products, ranging from proteinaceous toxins to capsular polysaccharides. The hemolysin export system consists of three proteins, HlyB, HlyD, and TolC. HlyB is a large protein, with 707 amino acids, which has several transmembrane helices and a conserved ATP binding site. HlyD is a protein with 477 amino acids and one transmembrane helix. It is proposed that a dimer of HlyB becomes embedded in the inner membrane. A dimer of HlyD interacts with the HlyB complex and TolC such that a channel spanning the periplasmic space is formed. TolC is an outer membrane protein. HlyB and HlyD are part of the hemolysin operon, while TolC is not. Other components of the operon encode HlyC, which aids in toxin activation, and HlyA, the alpha-hemolysin structural gene. Like the case for hemolysin A, the genetic determinants for the transport and processing of many bacteriocins are located near the bacteriocin structural gene and may or may not be in the same operon (reviewed in reference 16). Additional bacteriocin systems which encode proteins homologous to HlyB and other ABC transporters include the following (reviewed in reference 9): colicin V and microcin B17 of E. coli, nisin and lactococin G of L. lactis, epidermin of Staphylococcus epidermidis, gallidermin of Staphylococcus gallidermidis, subtilin of Bacillus subtilis, and the hemolysin-bacteriocin of E. faecalis. Thus, there appears to be a dedicated processing and secretion system for these antimicrobial peptides which is common among all bacteriocin-producing strains. The heterologous expression of lactacin F in C. piscicola LV17 provides evidence that these systems are highly similar and potentially interchangeable.
The proteolytic cleavage site that releases the mature bacteriocin from the intracellular precursor is conserved among numerous bacteriocins (10, 13, 28; , is predicted to break the alpha-helical structure of the N terminus of the precursor and provoke a beta-turn, such that the processing region is exposed to the action of a specific protease (19) . However, site-directed mutations designed to disrupt the betaturn conformation did not inhibit lactacin F activity as long as the Gly-Gly sequence was conserved (10) . This indicates that processing specificity relies heavily on sequence recognition in this region. Comparison of the N-terminal sequences of LafA, LafX, and carnobacteriocins A, BM1, and B2 reveals a high degree of conservation and homology (Fig. 4) : a hydrophobic residue at position Ϫ4; Leu or Met at position Ϫ7; an acidic (Asp or Glu) residue and Lys at positions Ϫ8 and Ϫ9, respectively; Ser or Asn at position Ϫ11; Leu at position Ϫ12; and Lys or Asn and Met at positions Ϫ17 and Ϫ18, respectively. LafX is the exception, with Lys and Met located at positions Ϫ13 and Ϫ14, respectively. The degree of sequence homology supports the importance of sequence recognition. Perhaps the class II bacteriocin precursors have the same requirements as the signal sequence of alpha-hemolysin, which has been proposed to have important contact residues required for processing and secretion (reviewed in reference 9). In the case of the bacteriocins, these contact residues may be important for specific interactions with the processing peptidase. C. piscicola LV17 expresses the lactacin F peptides at a low level relative to the carnobacteriocins. This may suggest that the subtle differences between the N-terminal extension sequences are such that the LafA and LafX precursors compete inefficiently for the native processing and excretion recognition signals. Alternatively, the Lactobacillus transcription and translation signals may not be proficiently read in the C. piscicola background. Unfortunately, little is known about the regulation of these bacteriocins. Sequence analysis of the area upstream of the cbnB2 gene have identified possible Ϫ10 and Ϫ35 regions that are similar to E. coli 70 and B. subtilis 43 promoter sequences (28) . The Ϫ10 promoter region of cbnA contains a TG sequence which is conserved in some grampositive promoters (41) . Analysis of the transcriptional start site and upstream promoter region of the lactacin F operon did not reveal any similarities to vegetative promoter sequences, and it has been suggested that the operon may be regulated (10) . Further analysis is required to gain insight into the low levels of expression of the heterologous genes in C. piscicola. Lactacin F and the carnobacteriocins are examples of class II bacteriocins which have several biochemical and structural characteristics in common. The mature forms of these peptides are predicted to form amphiphilic helices or beta sheets with variable hydrophobicity. It has been proposed that these amphiphilic helices and beta sheets interact with one another to form pores in the cytoplasmic membrane by means of the barrel stave mechanism (25) . In the case of lactococcin G and lactacin F, two heterologous peptides interact with one another to form the poration complex and the complementary peptides are predicted to form transmembrane helices (1, 4, 24) . Given the hydrophobic nature of LafA and LafX (17) , interaction of these two peptides may be promoted by hydrophobic forces. Analysis of the amino acid sequences of carnobacteriocins A and BM1 by the method of Rao and Argos (29) predicts the formation of transmembrane helices between amino acids 40 to 67 and 43 to 60, respectively. These putative transmembrane helices occur in the hydrophobic C-terminal regions of both peptides. Because LV17 produces LafA, LafX, and the lactacin F complex simultaneously with the native carnobacteriocins, the possibility that combined bacteriocin systems and/or components thereof could interact in a novel way to form an active heterologous complex was investigated. Heterologous combinations of peptides did not increase the inhibitory spectra beyond that of lactacin F and carnobacteriocins. Several explanations are possible. The nature of the interaction of LafA and LafX is unknown, and peptide interactions may be highly specific, as is the case for the model proposed for cecropin, a cationic, antimicrobial peptide produced by silkworms (8) . The model predicts that six cecropin peptides, each of which is in a helix-bend-helix motif, specifically interact with one another to form pores in lipid membranes (8) . Finally, bacteriocin interactions with sensitive cells are also poorly understood, and the requirement for receptors varies between bacteriocins. Nisin, for example, acts on energized liposomes and does not require a protein receptor, whereas lactococcin A does (12, 18) . If receptors are necessary for both the carnobacteriocins and lactacin F, receptor-bacteriocin interactions may be highly specific but not altered by peptide interactions between bacteriocins if these interactions occur.
Heterologous expression of bacteriocins has often included cloning of the processing and excretion system along with the bacteriocin structural gene. Examples of heterologous expression of both a bacteriocin and its export machinery have been illustrated in the production of pediocin PA-1 by E. coli (21) and epidermin by Staphylococcus carnosus (32, 33) . In the lactacin F experiments reported here, the bacteriocin operon, which comprises the structural bacteriocin genes and open reading frame encoding the putative immunity protein, or only the individual bacteriocin genes, were introduced into the heterologous hosts. Other reports of this type of heterologous expression have included the production of lactacin F by Leuconostoc gelidum UAL187-22 (16, 17) , helveticin J by L. johnsonii NCK64 (11, 15) , and acidocin B by L. plantarum 80 (20, 27) .
Insight into the heterologous expression of lactacin F by C. piscicola LV17 provides the basis for cloning other broadrange bacteriocins into fermentative lactic acid bacteria. Moreover, insight into bacteriocin processing and excretion could be exploited to produce other peptides of interest via this dedicated pathway. Ultimately, this could not only improve the safety and longevity of fermented dairy products but could also lead to the development of new and novel, value-added food products.
